Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

20151,396 citationsJournal Articlebronze Open Access

Authors

Robert J. Mayer · Azienda Ospedaliera Universitaria Pisana

Eric Van Cutsem · KU Leuven

Alfredo Falcone · University of Pisa

Takayuki Yoshino · National Cancer Center Hospital East

Rocio García‐Carbonero · Hebron University

Nobuyuki Mizunuma · Centre Eugène Marquis

Kentaro Yamazaki

Abstract

In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 20, pp. 1909-1919

DOI: 10.1056/nejmoa1414325

Field-Weighted Citation Impact: 48.28